TS 963
Latest Information Update: 14 Nov 2006
At a glance
- Originator Taisho Pharmaceutical
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis; Transient ischaemic attacks
Most Recent Events
- 09 Oct 2001 No-Development-Reported for Thrombosis in Japan (PO)
- 09 Oct 2001 No-Development-Reported for Transient ischaemic attacks in Japan (PO)
- 13 Aug 1998 New profile